Du He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Du He has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Bi Zhao
Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
1 shared publicationChengnong Guan
1 shared publication- Hongzhen Zhong
Department of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, 515041, No 69 Dongxia Road, Shantou, China
1 shared publication - Huifang Shang
Department of Neurology, Rare Disease Center, Laboratory of Neurodegenerative Disorders West China Hospital, Sichuan University Chengdu China
1 shared publication - Jiajia Fu
Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
1 shared publication - Jing Yang
Department of Neurology, Rare Disease Center, Laboratory of Neurodegenerative Disorders West China Hospital, Sichuan University Chengdu China
1 shared publication
Latest Publications
- Open Access
- 19 December 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1301109
Anti-SRP immune-mediated necrotizing myopathy responsive to ofatumumab: a case report
Background: Immune-mediated necrotizing myopathies (IMNM) is a rare disease that was first described in 2004. Due to the lack of large case series, there are no formal treatment recommendations for IMNM.Methods: We presented a case of a 47-year-old woman who experienced progressive limb weakness, starting from the lower limbs and gradually affecting the upper limbs. She also reported experiencing dyspnea after engaging in daily activities. When she was admitted to the hospital, her upper limbs were almost unable to move and she could not stand even with support. Her Creatine kinase (CK) level significantly increased (> 3500 u/l). Electromyography showed myogenic damage, anti-Signal recognition particle (anti-SRP) and anti-Ro52 antibodies were highly positive. Pathological biopsy of the right biceps muscle showed necrotizing myopathy in the skeletal muscle. She was ultimately diagnosed with anti-SRP IMNN, and was given monotherapy with methylprednisolone and combination therapy with immunoglobulin, but her symptoms continued to worsen. The patient refused to bear the possible further liver dysfunction and blood system damage caused by Cyclophosphamide and Rituximab, and she chose to try to use Ofatumumab (OFA).Results: After receiving three doses of OFA treatment without any adverse reactions, she reported that her muscle strength had basically recovered and she was able to walk independently. The B cells in the circulatory system have been depleted, and blood markers such as liver function have consistently remained within normal range. During the follow up, her activity tolerance continued to improve.Discussion: We have presented a severe case of SRP-IMNM in which the patient showed poor response to conventional immunotherapy. However, rapid symptom relief was achieved with early sequential use of OFA treatment. This provides a new option for the treatment of SRP-IMNM, and more large-scale studies will be needed in the future to verify our results.
- 19 December 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1301109
Open AccessAnti-SRP immune-mediated necrotizing myopathy responsive to ofatumumab: a case report
Background: Immune-mediated necrotizing myopathies (IMNM) is a rare disease that was first described in 2004. Due to the lack of large case series, there are no formal treatment recommendations for IMNM.Methods: We presented a case of a 47-year-old woman who experienced progressive limb weakness, starting from the lower limbs and gradually affecting the upper limbs. She also reported experiencing dyspnea after engaging in daily activities. When she was admitted to the hospital, her upper limbs were almost unable to move and she could not stand even with support. Her Creatine kinase (CK) level significantly increased (> 3500 u/l). Electromyography showed myogenic damage, anti-Signal recognition particle (anti-SRP) and anti-Ro52 antibodies were highly positive. Pathological biopsy of the right biceps muscle showed necrotizing myopathy in the skeletal muscle. She was ultimately diagnosed with anti-SRP IMNN, and was given monotherapy with methylprednisolone and combination therapy with immunoglobulin, but her symptoms continued to worsen. The patient refused to bear the possible further liver dysfunction and blood system damage caused by Cyclophosphamide and Rituximab, and she chose to try to use Ofatumumab (OFA).Results: After receiving three doses of OFA treatment without any adverse reactions, she reported that her muscle strength had basically recovered and she was able to walk independently. The B cells in the circulatory system have been depleted, and blood markers such as liver function have consistently remained within normal range. During the follow up, her activity tolerance continued to improve.Discussion: We have presented a severe case of SRP-IMNM in which the patient showed poor response to conventional immunotherapy. However, rapid symptom relief was achieved with early sequential use of OFA treatment. This provides a new option for the treatment of SRP-IMNM, and more large-scale studies will be needed in the future to verify our results.
- RetractionOpen Access
- 1 March 2023
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 16, 213-214
Matrine Suppresses the Migration and Invasion of NSCLC Cells by Inhibiting PAX2-Induced Epithelial-Mesenchymal Transition [Retraction]
Retraction for the article Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition
- 1 March 2023
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 16, 213-214
RetractionOpen AccessMatrine Suppresses the Migration and Invasion of NSCLC Cells by Inhibiting PAX2-Induced Epithelial-Mesenchymal Transition [Retraction]
Retraction for the article Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition
- Open Access
- 15 July 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 12 (7) , 705-718
Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: differences in basic biology and treatment
In 2017 the World Health Organization revised the criteria for classification of pancreatic neuroendocrine neoplasms (pNENs) after a consensus conference at the International Agency for Research on Cancer. The major change in the new classification was to subclassify the original G3 group into well-differentiated pancreatic neuroendocrine tumors G3 (pNETs G3) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs), which have been gradually proven to be completely different in biological behavior and clinical manifestations in recent years. In 2019 this major change subsequently extended to NENs involving the entire digestive tract. The updated version of the pNENs grading system marks a growing awareness of these heterogeneous tumors. This review discusses the clinicopathological, genetic and therapeutic features of poorly differentiated pNECs and compare them to those of well-differentiated pNETs G3. For pNETs G3 and pNECs (due to their lower incidence), there are still many problems to be investigated. Previous studies under the new grading classification also need to be reinterpreted. This review summarizes the relevant literature from the perspective of the differences between pNETs G3 and pNECs in order to deepen understanding of these diseases and discuss future research directions.
- 15 July 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 12 (7) , 705-718
Open AccessPancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: differences in basic biology and treatment
In 2017 the World Health Organization revised the criteria for classification of pancreatic neuroendocrine neoplasms (pNENs) after a consensus conference at the International Agency for Research on Cancer. The major change in the new classification was to subclassify the original G3 group into well-differentiated pancreatic neuroendocrine tumors G3 (pNETs G3) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs), which have been gradually proven to be completely different in biological behavior and clinical manifestations in recent years. In 2019 this major change subsequently extended to NENs involving the entire digestive tract. The updated version of the pNENs grading system marks a growing awareness of these heterogeneous tumors. This review discusses the clinicopathological, genetic and therapeutic features of poorly differentiated pNECs and compare them to those of well-differentiated pNETs G3. For pNETs G3 and pNECs (due to their lower incidence), there are still many problems to be investigated. Previous studies under the new grading classification also need to be reinterpreted. This review summarizes the relevant literature from the perspective of the differences between pNETs G3 and pNECs in order to deepen understanding of these diseases and discuss future research directions.